Modular Medical (MODD) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

MODD Modular Medical

Watchlist

1.630
+0.030+1.88%

Close Nov 26 16:00 ET

56.35MMarket Cap-2507P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Insider Purchase: Chief Executive Officer of $MODD (MODD) Buys 166,666 Shares
Quiver QuantitativeNov 25 20:01 ET
Exchange-Traded Funds, Equity Futures Edge Lower Pre-Bell Friday Ahead of Business Activity Data
MT NewswiresNov 22 08:30 ET
Reported Earlier, Modular Medical Prices $8.2M Public Offering Of 5,450,573 Common Shares At $1.50/Share
BenzingaNov 22 01:54 ET
Modular Medical Drops 8%, Prices $8.2M Stock
Seeking AlphaNov 22 01:41 ET
Modular Medical Announces Proposed Public Offering
AccesswireNov 21 16:05 ET
Modular Medical | 10-Q: Q2 2025 Earnings Report
SECNov 14 17:04 ET · Announcements

Comments

Jaguar8

Nov 7 07:20

NEWS

$Modular Medical (MODD.US)$
Modular Medical Announces Results from a Successful GLP-1 Proof of Concept Study
Modular Medical (NASDAQ:MODD) announced successful results from its pre-clinical GLP-1 proof of concept study. The study demonstrated enhanced weight loss and blood glucose control using a pump-delivered rapid-acting GLP-1 with both basal and bolus dosing. The highest basal-bolus dose achieved 17.1% weight loss at 28 days, compared to 13.7% with basal alone. All dosing variations outpe...

Trytosaveabit

Sep 18 07:06

News

$Modular Medical (MODD.US)$ Modular Medical Announces Issuance of U.S. Patent Covering Key Aspects of Core Pumping Technology
Accesswire· 5 mins ago

BeastMY

Sep 11 08:37

$Modular Medical (MODD.US)$ ok buy some before webinar to see the marketing plan. Will long if good

Trytosaveabit

Sep 11 07:07

Update

$Modular Medical (MODD.US)$ Modular Medical Announces Finalization of Protocol for GLP-1 Personalized Metabolic Therapy Study Utilizing the MODD1 Platform
ACCESSWIRE 11-Sep-2024 8:02 AM
-Proof of Concept Study in Rapid Acting GLP-1 to commence in October 2024 with data expected in November 2024
-Pre-clinical study to explore use of MODD1 pump as a personalized delivery system for people who discontinue long-acting GLP-1 formulations
-CEO to discuss further details of the program in Tribe Pu...